These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 31251472)

  • 1. C57BL/6 congenic mouse NRAS
    Petit V; Raymond J; Alberti C; Pouteaux M; Gallagher SJ; Nguyen MQ; Aplin AE; Delmas V; Larue L
    Pigment Cell Melanoma Res; 2019 Nov; 32(6):829-841. PubMed ID: 31251472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAF
    Jandova J; Wondrak GT
    J Invest Dermatol; 2022 May; 142(5):1456-1465.e1. PubMed ID: 34687745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion.
    Nörz D; Grottke A; Bach J; Herzberger C; Hofmann BT; Nashan B; Jücker M; Ewald F
    Cell Signal; 2015 Nov; 27(11):2191-200. PubMed ID: 26210887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.
    Kwong LN; Costello JC; Liu H; Jiang S; Helms TL; Langsdorf AE; Jakubosky D; Genovese G; Muller FL; Jeong JH; Bender RP; Chu GC; Flaherty KT; Wargo JA; Collins JJ; Chin L
    Nat Med; 2012 Oct; 18(10):1503-10. PubMed ID: 22983396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.
    Vu HL; Aplin AE
    Mol Cancer Res; 2014 Oct; 12(10):1509-19. PubMed ID: 24962318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binimetinib for the treatment of NRAS-mutant melanoma.
    Queirolo P; Spagnolo F
    Expert Rev Anticancer Ther; 2017 Nov; 17(11):985-990. PubMed ID: 28851243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MEK inhibitors for the treatment of NRAS mutant melanoma.
    Sarkisian S; Davar D
    Drug Des Devel Ther; 2018; 12():2553-2565. PubMed ID: 30154648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.
    Malka-Mahieu H; Girault I; Rubington M; Leriche M; Welsch C; Kamsu-Kom N; Zhao Q; Desaubry L; Vagner S; Robert C
    Cell Cycle; 2016 Sep; 15(18):2405-9. PubMed ID: 27533468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Local Inhibition of MEK/Akt Prevents Cellular Growth in Human Congenital Melanocytic Nevi.
    Rouillé T; Aractingi S; Kadlub N; Fraitag S; How-Kit A; Daunay A; Hivelin M; Moguelet P; Picard A; Fontaine RH; Guégan S
    J Invest Dermatol; 2019 Sep; 139(9):2004-2015.e13. PubMed ID: 31059696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer.
    Queralt B; Cuyàs E; Bosch-Barrera J; Massaguer A; de Llorens R; Martin-Castillo B; Brunet J; Salazar R; Menendez JA
    Oncotarget; 2016 Dec; 7(50):82185-82199. PubMed ID: 27636997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated mutant NRas(Q61K) drives aberrant melanocyte signaling, survival, and invasiveness via a Rac1-dependent mechanism.
    Li A; Ma Y; Jin M; Mason S; Mort RL; Blyth K; Larue L; Sansom OJ; Machesky LM
    J Invest Dermatol; 2012 Nov; 132(11):2610-21. PubMed ID: 22718121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade.
    Kiessling MK; Oberholzer PA; Mondal C; Karpova MB; Zipser MC; Lin WM; Girardi M; Macconaill LE; Kehoe SM; Hatton C; French LE; Garraway LA; Polier G; Süss D; Klemke CD; Krammer PH; Gülow K; Dummer R
    Blood; 2011 Feb; 117(8):2433-40. PubMed ID: 21209378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Lim SY; Menzies AM; Rizos H
    Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting NRAS in melanoma.
    Kelleher FC; McArthur GA
    Cancer J; 2012; 18(2):132-6. PubMed ID: 22453013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
    Krepler C; Xiao M; Sproesser K; Brafford PA; Shannan B; Beqiri M; Liu Q; Xu W; Garman B; Nathanson KL; Xu X; Karakousis GC; Mills GB; Lu Y; Ahmed TA; Poulikakos PI; Caponigro G; Boehm M; Peters M; Schuchter LM; Weeraratna AT; Herlyn M
    Clin Cancer Res; 2016 Apr; 22(7):1592-602. PubMed ID: 26673799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma.
    Wei BR; Michael HT; Halsey CH; Peer CJ; Adhikari A; Dwyer JE; Hoover SB; El Meskini R; Kozlov S; Weaver Ohler Z; Figg WD; Merlino G; Simpson RM
    Pigment Cell Melanoma Res; 2016 Nov; 29(6):643-655. PubMed ID: 27463366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of melanoma development in the Nras((Q61K)) ::Ink4a(-/-) mouse model by the small molecule BI-69A11.
    Feng Y; Lau E; Scortegagna M; Ruller C; De SK; Barile E; Krajewski S; Aza-Blanc P; Williams R; Pinkerton AB; Jackson M; Chin L; Pellecchia M; Bosenberg M; Ronai ZA
    Pigment Cell Melanoma Res; 2013 Jan; 26(1):136-42. PubMed ID: 23035722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.
    Silva JM; Deuker MM; Baguley BC; McMahon M
    Pigment Cell Melanoma Res; 2017 May; 30(3):353-367. PubMed ID: 28233937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma.
    Posch C; Cholewa BD; Vujic I; Sanlorenzo M; Ma J; Kim ST; Kleffel S; Schatton T; Rappersberger K; Gutteridge R; Ahmad N; Ortiz/Urda S
    J Invest Dermatol; 2015 Oct; 135(10):2475-2483. PubMed ID: 26016894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.